Literature DB >> 18621722

Class 1A PI3K regulates vessel integrity during development and tumorigenesis.

Tina L Yuan1, Hak Soo Choi, Aya Matsui, Cyril Benes, Eugene Lifshits, Ji Luo, John V Frangioni, Lewis C Cantley.   

Abstract

PI3K is important in the regulation of growth, proliferation, and survival of tumor cells. We show that class 1A PI3K is also critical in the tumor microenvironment by regulating the integrity of the tumor vasculature. Using Tie2Cre-mediated deletion of the PI3K regulatory subunits (p85alpha, p55alpha, p50alpha, and p85beta), we generated mice with endothelial cell-specific loss of class 1A PI3K. Complete loss of all subunits caused acute embryonic lethality at E11.5 due to hemorrhaging, whereas retention of a single p85alpha allele yielded viable mice that survived to adulthood. These heterozygous mice exhibited no vascular defects until challenged with a pathological insult, such as tumor cells or high levels of VEGF. Under these pathological conditions, heterozygous mice exhibited localized vascular abnormalities, including vessel leakage and the inability to maintain large vessels, which caused a deceleration of tumorigenesis. Furthermore, we show that a PI3K inhibitor can mimic the effects of class 1A PI3K loss, which suggests that targeting class 1A PI3K may be a promising therapy for blocking tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18621722      PMCID: PMC2453070          DOI: 10.1073/pnas.0804123105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  In vivo and in vitro models of Mammalian angiogenesis.

Authors:  Mien V Hoang; Donald R Senger
Journal:  Methods Mol Biol       Date:  2005

2.  Microvascular patterning is controlled by fine-tuning the Akt signal.

Authors:  Jing Fang Sun; Thuy Phung; Ichiro Shiojima; Terri Felske; J Nalinee Upalakalin; Dian Feng; Tad Kornaga; Talia Dor; Ann M Dvorak; Kenneth Walsh; Laura E Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

3.  Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit.

Authors:  J Yu; Y Zhang; J McIlroy; T Rordorf-Nikolic; G A Orr; J M Backer
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

4.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

Authors:  Yardena Samuels; Luis A Diaz; Oleg Schmidt-Kittler; Jordan M Cummins; Laura Delong; Ian Cheong; Carlo Rago; David L Huso; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

5.  Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement.

Authors:  Saskia M Brachmann; Claudine M Yballe; Metello Innocenti; Jonathan A Deane; David A Fruman; Sheila M Thomas; Lewis C Cantley
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

6.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

Authors:  Jeffrey A Engelman; Pasi A Jänne; Craig Mermel; Joseph Pearlberg; Toru Mukohara; Christina Fleet; Karen Cichowski; Bruce E Johnson; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-24       Impact factor: 11.205

Review 7.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

8.  The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis.

Authors:  Koichi Hamada; Takehiko Sasaki; Pandelakis A Koni; Miyuki Natsui; Hiroyuki Kishimoto; Junko Sasaki; Nobuyuki Yajima; Yasuo Horie; Go Hasegawa; Makoto Naito; Jun-Ichi Miyazaki; Toshio Suda; Hiroshi Itoh; Kazuwa Nakao; Tak Wah Mak; Toru Nakano; Akira Suzuki
Journal:  Genes Dev       Date:  2005-08-17       Impact factor: 11.361

9.  Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice.

Authors:  Tatsuo Furuyama; Kazuko Kitayama; Yuri Shimoda; Minetaro Ogawa; Kiyoaki Sone; Kiyomi Yoshida-Araki; Hiroshi Hisatsune; Shin-ichi Nishikawa; Keiko Nakayama; Keiichi Nakayama; Kyoji Ikeda; Noboru Motoyama; Nozomu Mori
Journal:  J Biol Chem       Date:  2004-06-07       Impact factor: 5.157

10.  Measuring hemodynamic changes during mammalian development.

Authors:  E A V Jones; M H Baron; S E Fraser; M E Dickinson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-05-20       Impact factor: 4.733

View more
  37 in total

1.  PDK1 regulates vascular remodeling and promotes epithelial-mesenchymal transition in cardiac development.

Authors:  Qiuting Feng; Ruomin Di; Fang Tao; Zai Chang; Shuangshuang Lu; Wenjing Fan; Congjia Shan; Xinli Li; Zhongzhou Yang
Journal:  Mol Cell Biol       Date:  2010-05-10       Impact factor: 4.272

Review 2.  Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.

Authors:  Nathan T Ihle; Garth Powis
Journal:  Mol Aspects Med       Date:  2010-02-20

3.  TGFβ1 exacerbates blood-brain barrier permeability in a mouse model of hepatic encephalopathy via upregulation of MMP9 and downregulation of claudin-5.

Authors:  Matthew A McMillin; Gabriel A Frampton; Andrew P Seiwell; Nisha S Patel; Amber N Jacobs; Sharon DeMorrow
Journal:  Lab Invest       Date:  2015-06-01       Impact factor: 5.662

Review 4.  Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.

Authors:  L G Estévez; E García; M Hidalgo
Journal:  Clin Transl Oncol       Date:  2015-10-28       Impact factor: 3.405

Review 5.  Clinical development of phosphatidylinositol-3 kinase pathway inhibitors.

Authors:  Carlos L Arteaga
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 6.  PI3K: A Crucial Piece in the RAS Signaling Puzzle.

Authors:  Agata Adelajda Krygowska; Esther Castellano
Journal:  Cold Spring Harb Perspect Med       Date:  2018-06-01       Impact factor: 6.915

7.  Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.

Authors:  Enrique González-Billalabeitia; Nina Seitzer; Su Jung Song; Min Sup Song; Akash Patnaik; Xue-Song Liu; Mirjam T Epping; Antonella Papa; Robin M Hobbs; Ming Chen; Andrea Lunardi; Christopher Ng; Kaitlyn A Webster; Sabina Signoretti; Massimo Loda; John M Asara; Caterina Nardella; John G Clohessy; Lewis C Cantley; Pier Paolo Pandolfi
Journal:  Cancer Discov       Date:  2014-05-27       Impact factor: 39.397

8.  The PI3K p110alpha isoform regulates endothelial adherens junctions via Pyk2 and Rac1.

Authors:  Robert J Cain; Bart Vanhaesebroeck; Anne J Ridley
Journal:  J Cell Biol       Date:  2010-03-22       Impact factor: 10.539

Review 9.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 10.  Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.

Authors:  Arkaitz Carracedo; Jose Baselga; Pier Paolo Pandolfi
Journal:  Cell Cycle       Date:  2008-12-22       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.